{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Cullinan Therapeutics Hits New 52-Week Low at $5.89
Cullinan Therapeutics, Inc. has reached a new 52-week low, reflecting a difficult year with a significant stock price decline. The company, with a market capitalization of approximately USD 404 million, is currently operating at a loss and has a price-to-book ratio indicating it is valued below its book value.
Cullinan Therapeutics Hits New 52-Week Low at $6.24 Amidst Major Decline
Cullinan Therapeutics, Inc. has reached a new 52-week low, reflecting a significant decline in its stock performance over the past year. The company, with a market capitalization of approximately USD 404 million, is currently operating at a loss and shows challenging financial metrics, indicating a volatile environment in the biotechnology sector.
Cullinan Therapeutics Hits New 52-Week Low at $6.32
Cullinan Therapeutics, Inc. has reached a new 52-week low, reflecting a significant decline from its previous high. The company, with a market capitalization of USD 404 million, is currently operating at a loss and shows a negative return on equity. Its financial structure includes a low price-to-book ratio and no dividend yield.
Is Cullinan Therapeutics, Inc. overvalued or undervalued?
As of May 16, 2022, Cullinan Therapeutics, Inc. is considered overvalued with a valuation grade of "does not qualify," reflecting poor financial metrics and a year-to-date stock performance of -37.77%, significantly underperforming the S&P 500's 2.44% return.
Is Cullinan Therapeutics, Inc. technically bullish or bearish?
As of June 9, 2025, Cullinan Therapeutics, Inc. exhibits a mildly bearish trend, influenced by daily moving averages and weekly Bollinger Bands, despite mixed signals from the MACD and RSI across different timeframes.
What does Cullinan Therapeutics, Inc. do?
Cullinan Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $49 million and a market cap of $491 million. Key financial metrics include a negative P/E ratio, a 0.00% dividend yield, and a return on equity of -32.39%.
How big is Cullinan Therapeutics, Inc.?
As of Jun 18, Cullinan Therapeutics, Inc. has a market capitalization of 491.00 million, with net sales of 0.00 million and a net profit of -178.74 million over the latest four quarters. Shareholder's funds are at 590.33 million, and total assets are 622.43 million as of Dec 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
